Nanoparticle drug delivery system for restenosis

[1]  R. Levy,et al.  Iontophoresis for modulation of cardiac drug delivery in dogs. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Y. Kawashima,et al.  In vitro drug release behavior of D,L-lactide/glycolide copolymer (PLGA) nanospheres with nafarelin acetate prepared by a novel spontaneous emulsification solvent diffusion method. , 1994, Journal of pharmaceutical sciences.

[3]  D. Bazile,et al.  Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. , 1995, Journal of pharmaceutical sciences.

[4]  A. Buchwald,et al.  Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. , 1993, Journal of the American College of Cardiology.

[5]  J. Kreuter,et al.  Distribution and elimination of poly(methyl methacrylate) nanoparticles after subcutaneous administration to rats. , 1983, Journal of pharmaceutical sciences.

[6]  S. Epstein,et al.  Gene therapy for vascular disease , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  I. Fichtner,et al.  Influence of polybutylcyanoacrylate nanoparticles and liposomes on the efficacy and toxicity of the anticancer drug mitoxantrone in murine tumour models. , 1993, Journal of microencapsulation.

[8]  J. Poupaert,et al.  Poly(diethyl methylidenemalonate) nanoparticles as a potential drug carrier: preparation, distribution and elimination after intravenous and peroral administration to mice. , 1991, Journal of pharmaceutical sciences.

[9]  Robert J. Levy,et al.  Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery , 1997 .

[10]  P. Couvreur,et al.  Comparative cell uptake of propidium iodide associated with liposomes or nanoparticles. , 1987, Cellular and molecular biology.

[11]  E. Edelman,et al.  Antisense proliferating cell nuclear antigen oligonucleotides inhibit intimal hyperplasia in a rat carotid artery injury model. , 1994, The Journal of clinical investigation.

[12]  V. Labhasetwar,et al.  Nanoparticles - a colloidal drug delivery system for primaquine and metronidazole. , 1990 .

[13]  J. Isner,et al.  Gene therapy for the vulnerable plaque. , 1995, Journal of the American College of Cardiology.

[14]  F. Opperdoes,et al.  Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani. , 1992, Annals of tropical medicine and parasitology.

[15]  J. Heller.  Polymers for controlled parenteral delivery of peptides and proteins , 1993 .

[16]  S. Humphries,et al.  Vascular disease: the next target for local molecular therapeutics , 1994, BMJ.

[17]  V. Fuster,et al.  Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. , 1994, Circulation.

[18]  L. Balant,et al.  Internalization of poly(D,L-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles. , 1994, Journal of biomedical materials research.

[19]  R. Müller,et al.  The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. , 1995, Advanced drug delivery reviews.

[20]  V. Fuster,et al.  A new approach for local intravascular drug delivery. Iontophoretic balloon. , 1994, Circulation.

[21]  V. Lenaerts,et al.  New method for the preparation of cyanoacrylic nanoparticles with improved colloidal properties. , 1989, Journal of pharmaceutical sciences.

[22]  P. Serruys,et al.  A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators. , 1995, The New England journal of medicine.

[23]  H. Lundqvist,et al.  Pathophysiological mechanisms for restenosis following coronary angioplasty: possible preventive alternatives , 1993, Journal of internal medicine.

[24]  P. Couvreur,et al.  Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. , 1994, European journal of cancer.

[25]  J. Kreuter,et al.  Nanoparticles as drug carriers in ophthalmology. , 1987, Pharmaceutica acta Helvetiae.

[26]  J. Kreuter,et al.  Possibilities of using nanoparticles as carriers for drugs and vaccines. , 1988, Journal of microencapsulation.

[27]  T. Ivanova,et al.  Nanoparticles as drug carriers for vinblastine. Acute toxicity of vinblastine in a free form and associated to polybutylcyanoacrylate nanoparticles. , 1991, Acta physiologica et pharmacologica Bulgarica.

[28]  M. Alonso,et al.  Improvement of Ocular Penetration of Amikacin Sulphate by Association to Poly(butylcyanoacrylate) Nanoparticles , 1991, The Journal of pharmacy and pharmacology.

[29]  J Kreuter,et al.  Evaluation of nanoparticles as drug-delivery systems. III: materials, stability, toxicity, possibilities of targeting, and use. , 1983, Pharmaceutica acta Helvetiae.

[30]  R. Kinne,et al.  In vitro permeability of PBCA nanoparticles through porcine small intestine. , 1993, Journal of drug targeting.

[31]  K. Mathias.  Local Thrombolysis for Salvage of Occluded Bypass Grafts , 1991, Seminars in thrombosis and hemostasis.

[32]  D. Hathaway,et al.  Biodegradable microspheres containing a colchicine analogue inhibit DNA synthesis in vascular smooth muscle cells. , 1994, Circulation.

[33]  B. Genetet,et al.  Flow cytometric quantitative evaluation of phagocytosis by human mononuclear and polymorphonuclear cells using fluorescent nanoparticles. , 1987, Journal of immunological methods.

[34]  P. Speiser,et al.  Nanoparticles--a new colloidal drug delivery system. , 1978, Pharmaceutica acta Helvetiae.

[35]  P. Couvreur,et al.  Experience with doxorubicin-bound polyisohexylcyanoacrylate nanoparticles on murine alveolar echinococcosis of the liver. , 1993, International journal for parasitology.

[36]  M. Papisov.  Modeling in vivo transfer of long-circulating polymers (two classes of long circulating polymers and factors affecting their transfer in vivo) , 1995 .

[37]  R. W. Wood,et al.  Ocular drug delivery of progesterone using nanoparticles. , 1986, Journal of microencapsulation.

[38]  A. Zimmer,et al.  Use of liposomes, viral capsids, and nanoparticles as DNA carriers , 1991, Biotechnology and applied biochemistry.

[39]  D. Wishka,et al.  Synthesis and biological evaluation of antiplatelet 2-aminochromones. , 1993, Journal of medicinal chemistry.

[40]  E. Edelman,et al.  c-myc in vasculoproliferative disease. , 1995, Circulation research.

[41]  I. Penn,et al.  Safety, success, and restenosis after elective coronary implantation of the Palmaz-Schatz stent in 100 patients at a single center. , 1993, American heart journal.

[42]  Ralph Weissleder,et al.  Long-circulating iron oxides for MR imaging , 1995 .

[43]  H. von Briesen,et al.  Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages. , 1994, Journal of microencapsulation.

[44]  M. Kerstein,et al.  Intraoperative intra-arterial urokinase infusion as an adjunct to Fogarty catheter embolectomy in acute arterial occlusion. , 1990, Surgery, gynecology & obstetrics.

[45]  G W Halbert,et al.  The Uptake and Translocation of Latex Nanospheres and Microspheres after Oral Administration to Rats , 1989, The Journal of pharmacy and pharmacology.

[46]  M. Bornschein,et al.  [Micro- and nanoparticles as carrier systems with special consideration of the preparation methods]. , 1989, Die Pharmazie.

[47]  J. Kreuter.  Nanoparticles and nanocapsules--new dosage forms in the nanometer size range. , 1978, Pharmaceutica acta Helvetiae.

[48]  E. Edelman,et al.  Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Benoit,et al.  In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. , 1995, Journal of drug targeting.

[50]  E. Topol,et al.  Dexamethasone-nanoparticles for intra-arterial localization in restenosis in rats , 1995 .

[51]  C. Hélène,et al.  Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[52]  J. Kreuter,et al.  Distribution and elimination of polymethyl methacrylate nanoparticles after peroral administration to rats. , 1984, Journal of pharmaceutical sciences.

[53]  E. Edelman,et al.  Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Waters,et al.  Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch catheter. , 1994, Catheterization and cardiovascular diagnosis.

[55]  M. Martin,et al.  Short-Term Ultrahigh Streptokinase Treatment of Chronic Arterial Occlusions and Acute Deep Vein Thromboses , 1991, Seminars in thrombosis and hemostasis.

[56]  C M Gibson,et al.  Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. , 1993, Journal of the American College of Cardiology.

[57]  D. Muller.  Gene therapy for cardiovascular disease. , 1994, British heart journal.

[58]  Samin K. Sharma,et al.  Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. , 1994, Journal of the American College of Cardiology.

[59]  P. Couvreur,et al.  The uptake of ampicillin-loaded nanoparticles by murine macrophages infected with Salmonella typhimurium. , 1994, Journal of Antimicrobial Chemotherapy.

[60]  H. Ronde,et al.  Preparation and Structure of a Water‐in‐Oil Cream Containing Lipid Nanoparticles , 1995 .

[61]  P. Couvreur,et al.  Nano- and microparticles for the delivery of polypeptides and proteins , 1993 .

[62]  P. Couvreur,et al.  Ampicillin-loaded liposomes and nanoparticles: comparison of drug loading, drug release and in vitro antimicrobial activity. , 1991, Journal of microencapsulation.

[63]  P. Couvreur,et al.  [Nanoparticles of doxorubicin: colloidal vectors in the treatment of hepatic metastases in animals]. , 1989, Bulletin du cancer.

[64]  G. Borchard,et al.  Interaction of serum components with poly(methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. , 1993, Journal of drug targeting.

[65]  J. Isner,et al.  Prospects for site-specific delivery of pharmacologic and molecular therapies. , 1994, Journal of the American College of Cardiology.

[66]  E. Nabel,et al.  Gene transfer and vascular disease. , 1994, Cardiovascular research.

[67]  H De Geest,et al.  Biocompatibility of polymer-coated oversized metallic stents implanted in normal porcine coronary arteries. , 1995, Atherosclerosis.

[68]  J. Isner,et al.  Arterial gene transfer using pure DNA applied directly to a hydrogel-coated angioplasty balloon. , 1993, Human gene therapy.

[69]  M. Mayberg,et al.  Localized release of perivascular heparin inhibits intimal proliferation after endothelial injury without systemic anticoagulation. , 1989, Neurosurgery.

[70]  H. Wolinsky.  Local delivery: let's keep our eyes on the wall. , 1994, Journal of the American College of Cardiology.

[71]  J. Kreuter.  [10] Poly(alkyl acrylate) nanoparticles , 1985 .

[72]  S. Nikol,et al.  Enhanced Migratory Activity of Vascular Smooth Muscle Cells with High Expression of Platelet-Derived Growth Factor A and B , 1995, Angiology.

[73]  D. Waters,et al.  Decreased Platelet Deposition and Smooth Muscle Cell Proliferation After Intramural Heparin Delivery With Hydrogel‐Coated Balloons , 1994, Circulation.

[74]  J. Kreuter,et al.  Long-term studies of microencapsulated and adsorbed influenza vaccine nanoparticles. , 1981, Journal of pharmaceutical sciences.

[75]  N Hussain,et al.  Factors affecting the oral uptake and translocation of polystyrene nanoparticles: histological and analytical evidence. , 1995, Journal of drug targeting.

[76]  J. Isner,et al.  Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery. , 1995, Circulation.

[77]  V. Torchilin,et al.  Which polymers can make nanoparticulate drug carriers long-circulating? , 1995 .

[78]  B. Manthey,et al.  Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats. , 1984, Journal of pharmaceutical sciences.

[79]  J. Labský,et al.  Fate of 14C-terpolymer (methylmethacrylate-14C, 2-hydroxyethylmethacrylate, butylacrylate) nanoparticles after peroral administration to rats. , 1989, Die Pharmazie.

[80]  P. Consigny,et al.  Drug delivery into the arterial wall: a time-course study with use of a lipophilic dye. , 1994, Journal of vascular and interventional radiology : JVIR.

[81]  P. Couvreur,et al.  Adsorption/desorption of human serum albumin at the surface of poly(lactic acid) nanoparticles prepared by a solvent evaporation process. , 1993, Journal of biomedical materials research.

[82]  M. Perricaudet,et al.  Arterial gene transfer to rabbit endothelial and smooth muscle cells using percutaneous delivery of an adenoviral vector. , 1994, Circulation.

[83]  R. Califf,et al.  Clinical trials of restenosis after coronary angioplasty. , 1991, Circulation.

[84]  R. Wilensky,et al.  Regional and arterial localization of radioactive microparticles after local delivery by unsupported or supported porous balloon catheters. , 1995, American heart journal.

[85]  P. Couvreur,et al.  Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. , 1989, Selective cancer therapeutics.

[86]  V. Fuster,et al.  The Three Processes Leading to Post PTCA Restenosis: Dependence on the Lesion Substrate , 1995, Thrombosis and Haemostasis.

[87]  J. Kostis,et al.  Coronary perfusion catheter: its effectiveness in an experimental model of acute coronary occlusion. , 1990, American heart journal.

[88]  E. Nabel.  Direct gene transfer into the arterial wall. , 1992, Journal of vascular surgery.

[89]  E. Nabel,et al.  Site-specific gene expression in vivo by direct gene transfer into the arterial wall. , 1990, Science.

[90]  J. Wilcox,et al.  Molecular biology: insight into the causes and prevention of restenosis after arterial intervention. , 1993, The American journal of cardiology.

[91]  E J Topol,et al.  Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. , 1996, Circulation.

[92]  T. Gray,et al.  Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes , 1994, FEBS letters.

[93]  E. Edelman,et al.  Contrasting Effects of the Intermittent and Continuous Administration of Heparin in Experimental Restenosis , 1994, Circulation.

[94]  J. Kreuter,et al.  Effect of nanoparticles on transdermal drug delivery. , 1991, Journal of microencapsulation.

[95]  J. Marmur,et al.  Excimer laser-facilitated balloon angioplasty of a nondilatable lesion. , 1991, Journal of the American College of Cardiology.

[96]  P. Couvreur,et al.  Nanoparticles as microcarriers for anticancer drugs , 1990 .

[97]  V. Torchilin,et al.  Biodegradable long-circulating polymeric nanospheres. , 1994, Science.

[98]  A. Coombes,et al.  Preparation of sub-100 nm human serum albumin nanospheres using a pH-coacervation method. , 1993, Journal of drug targeting.

[99]  J. Mustard,et al.  Acute administration of ethanol to rabbits inhibits thrombus formation induced by indwelling aortic catheters. , 1990, Laboratory investigation; a journal of technical methods and pathology.

[100]  M R Gasco,et al.  Optimization of doxorubicine incorporation and of the yield of polybutylcyanacrylate nanoparticles. , 1991, Pharmaceutica acta Helvetiae.

[101]  R. Perdrisot,et al.  Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. , 1991, Magnetic resonance imaging.

[102]  R. Wilensky,et al.  Methods and devices for local drug delivery in coronary and peripheral arteries. , 1993, Trends in cardiovascular medicine.

[103]  F J Schoen,et al.  Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. , 1985, Science.

[104]  H. von Briesen,et al.  Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. , 1994, Research in virology.

[105]  C. Hélène,et al.  Antisense effects of cholesterol-oligodeoxynucleotide conjugates associated with poly(alkylcyanoacrylate) nanoparticles. , 1995, European Journal of Biochemistry.

[106]  E. Edelman,et al.  Tissue engineered perivascular endothelial cell implants regulate vascular injury. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[107]  J. Kreuter,et al.  A solid colloidal drug delivery system for the eye: encapsulation of pilocarpin in nanoparticles. , 1986, Journal of microencapsulation.

[108]  S. Moghimi.  Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers , 1995 .

[109]  C. Haudenschild,et al.  Pathobiology of restenosis after angioplasty. , 1993, The American journal of medicine.

[110]  P. Couvreur,et al.  Disposition kinetics and oral bioavailability of vincamine-loaded polyalkyl cyanoacrylate nanoparticles. , 1986, Journal of pharmaceutical sciences.

[111]  D. Waters,et al.  Localized intramural drug delivery during balloon angioplasty using hydrogel-coated balloons and pressure-augmented diffusion. , 1994, Journal of the American College of Cardiology.

[112]  J. Robert,et al.  Doxorubicin encapsulation in liposomes and nanospheres for the reversal of multidrug resistance in vitro: 87 , 1994 .

[113]  J. Robert,et al.  [Intracellular accumulation of free doxorubicin and doxorubicin encapsulated in nanospheres]. , 1994, Biulleten' eksperimental'noi biologii i meditsiny.

[114]  S. King,et al.  Inhibition of platelet-dependent thrombosis by local delivery of heparin with a hydrogel-coated balloon. , 1995, Circulation.

[115]  G. Evan,et al.  Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. , 1994, The Journal of clinical investigation.

[116]  J. Kreuter,et al.  Influence of the surface properties of low contact angle surfactants on the body distribution of 14C-poly(methyl methacrylate) nanoparticles. , 1992, Journal of microencapsulation.

[117]  F Litvack,et al.  Localized Arterial Wall Drug Delivery From a Polymer‐Coated Removable Metallic Stent: Kinetics, Distribution, and Bioactivity of Forskolin , 1994, Circulation.

[118]  D. Baim,et al.  Restenosis after Arterial Injury Caused by Coronary Stenting in Patients with Diabetes Mellitus , 1993, Annals of Internal Medicine.

[119]  K. Caldwell,et al.  Surface modification of nanoparticles by PEO/PPO block copolymers to minimize interactions with blood components and prolong blood circulation in rats. , 1993, Biomaterials.

[120]  J. Wilcox.  Thrombin and other potential mechanisms underlying restenosis. , 1991, Circulation.

[121]  A. Buchwald,et al.  Restenosis after excimer laser angioplasty of coronary stenoses and chronic total occlusions. , 1992, American heart journal.

[122]  S. Epstein,et al.  The basis of molecular strategies for treating coronary restenosis after angioplasty. , 1994, Journal of the American College of Cardiology.

[123]  E. Nabel,et al.  Gene therapy for vascular smooth muscle cell proliferation after arterial injury. , 1994, Science.

[124]  R. Weissleder,et al.  Long-circulating blood pool imaging agents , 1995 .

[125]  D. Waters,et al.  Enhanced intracoronary thrombolysis with urokinase using a novel, local drug delivery system. In vitro, in vivo, and clinical studies. , 1995, Circulation.

[126]  Lisbeth Illum,et al.  Long circulating microparticulate drug carriers , 1995 .

[127]  R. Gurny,et al.  An investigation on the role of plasma and serum opsonins on the internalization of biodegradable poly(D,L-lactic acid) nanoparticles by human monocytes. , 1995, Life sciences.

[128]  J. Kreuter,et al.  Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles) , 1995, Brain Research.

[129]  P. Couvreur,et al.  Actinomycin D absorbed on polymethylcyanoacrylate nanoparticles: increased efficiency against an experimental tumor. , 1980, European journal of cancer.

[130]  R. Wilensky,et al.  Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. , 1991, American Heart Journal.

[131]  R. Levy,et al.  Local cyclosporine immunotherapy of heart transplants in rats enhances survival. , 1991, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[132]  M. Pitney,et al.  Use of twenty-four hour infusions of intracoronary tissue plasminogen activator to increase the application of coronary angioplasty. , 1992, Catheterization and cardiovascular diagnosis.

[133]  E. Topol,et al.  Effects of antisense c-myb oligonucleotides on vascular smooth muscle cell proliferation and response to vessel wall injury. , 1995, Circulation research.

[134]  E J Topol,et al.  Local drug delivery for the prevention of restenosis. Fact, fancy, and future. , 1994, Circulation.

[135]  J. Kreuter,et al.  Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. , 1983, Oncology.

[136]  J. Kreuter,et al.  Toxicity and association of polycyanoacrylate nanoparticles with hepatocytes. , 1984, Journal of microencapsulation.

[137]  D. Waters,et al.  Inhibition of platelet deposition and lysis of intracoronary thrombus during balloon angioplasty using urokinase-coated hydrogel balloons. , 1994, Circulation.

[138]  E. Topol,et al.  Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. , 1994, The Journal of clinical investigation.

[139]  R. Levy,et al.  Nanoparticles for site specific delivery of U-86983 in restenosis in pig coronary arteries , 1995 .

[140]  M. Bornschein,et al.  Mikro- und Nanopartikeln als Arzneistoffträgersysteme unter besonderer Berücksichtigung der Herstellungsmethoden , 1989 .

[141]  A. Rolland,et al.  Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained-release form, polymethacrylate nanospheres, in U-937 cells. , 1988, Cancer research.

[142]  T. Ogihara,et al.  A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[143]  R. McKay,et al.  Treatment of acute stent thrombosis with local urokinase therapy using catheter-based, drug delivery systems: a case report. , 1995, Catheterization and cardiovascular diagnosis.

[144]  J. Marmur,et al.  Induction of PDGF-responsive genes in vascular smooth muscle. Implications for the early response to vessel injury. , 1992, Circulation.

[145]  J. Langberg,et al.  Epicardial administration of ibutilide from polyurethane matrices: effects on defibrillation threshold and electrophysiologic parameters. , 1994, Journal of cardiovascular pharmacology.

[146]  J. Löwer,et al.  High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines , 1991, AIDS.

[147]  T Nagai,et al.  Preparation of polylactic acid-polylipoic acid nanospheres as drug targeting carriers. , 1987, Drug design and delivery.

[148]  K. Nilsson.  Preparation of nanoparticles conjugated with enzyme and antibody and their use in heterogeneous enzyme immunoassays. , 1989, Journal of immunological methods.

[149]  Michael Simons,et al.  Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo , 1992, Nature.

[150]  R. Levy,et al.  Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating. , 1987, Journal of pharmaceutical sciences.

[151]  Functionalized, probe-containing, latex nanospheres. , 1992, Analytical biochemistry.

[152]  T. Finkel,et al.  Do antisense approaches to the problem of restenosis make sense? , 1993, Circulation.

[153]  J. Wilcox,et al.  Thrombotic mechanisms in atherosclerosis: potential impact of soy proteins. , 1995, The Journal of nutrition.

[154]  M. Leon,et al.  Dose-dependent smooth muscle cell proliferation induced by thermal injury with pulsed infrared lasers , 1992, 1992 14th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[155]  E. Nabel,et al.  Gene therapy for cardiovascular disease. , 1995, Circulation.

[156]  J. D. Macklis,et al.  Restricted diffusion and stability of carbachol-fluorescent nanospheres in-vivo. , 1991, Neuroreport.

[157]  A. Maruyama,et al.  Preparation of nanoparticles bearing high density carbohydrate chains using carbohydrate-carrying polymers as emulsifier. , 1994, Biomaterials.

[158]  R. Virmani,et al.  Anatomic barriers influence the distribution of in vivo gene transfer into the arterial wall. Modeling with microscopic tracer particles and verification with a recombinant adenoviral vector. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[159]  S. Davis,et al.  Nanoparticles in drug delivery. , 1987, Critical reviews in therapeutic drug carrier systems.